The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | A Phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the Phase II DarPAL trial (NCT04895917), which investigated the combination of daratumumab (dara) and pomalidomide in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. This combination resulted in a high overall response rate and encouraging cardiac and renal responses. As expected, this treatment approach was associated with a significant rate of cytopenias, particularly neutropenia. Dr Milani highlights that the study was designed prior to the widespread use of dara in the frontline setting, meaning that the role of this combination therapy in patients who fail on frontline dara is not yet known. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Pfizer, Jannsen-Cilag
Membership on Board of Directors or advisory committee: Jannsen-Cilag, Siemens
